CONFIDENTIAL INFORMATION KnowTox, a Franco- Hungarian collaborative project relative to toxicity.

Slides:



Advertisements
Similar presentations
1 Szabolcs Csepregi*, Szilárd Dóránt, Nóra Máté, Miklós Vargyas, Péter Kovács, György Pirok, Ferenc Csizmadia First presented at Applications of Cheminformatics.
Advertisements

May, 2008 Presenting: Szabolcs Csepregi The ChemAxon Markush project overview and development discussion.
Integrating ChemAxon technology into your End User Applications Java solutions for cheminformatics Ver. Mar., 2005.
JKlustor clustering chemical libraries presented by … maintained by Miklós Vargyas Last update: 25 March 2010.
Version 5.3, April 2010 The ChemAxon Markush project overview and development discussion.
SOMA2 – Drug Design Environment. Drug design environment – SOMA2 The SOMA2 project Tekes (National Technology Agency of Finland) DRUG2000 program.
CeuticalSoft Discovery IT Solutions CeuticalSoft is a Life Science IT company offering products, services and customized solutions for Pharmaceutical and.
1 Miklós Vargyas May, 2005 Compound Library Annotation.
I mproved V irtual S creening S trategies and E nrichment of F ocused L ibraries in A ctive C ompounds U sing T arget- O riented D atabases I mproved.
Leveraging ChemAxon Cheminformatics in an Integrated Drug Discovery and Development Platform Zhenbin Li, Paul Starbard, Jim Gregory, Donald Chen, Paul.
Chemaxon's chemo-informatics toolkit integration into the Affectis Data Management System Database Automated Data Integration - Example: IC50 Data generated.
Introduction to Metabolizer
Partnering ChemAxon Nóra Lapusnyik, Alexander Drijver Solutions for Cheminformatics.
PUBLIC ChemAxon European UGM Building an Electronic Research Habitat at ETC Peter Condron.
1 Real World Chemistry Virtual discovery for the real world Joe Mernagh 19 May 2005.
JChem Node extension for KNIME Workbench
Solutions for Cheminformatics
The Drug Discovery Process
Adis R&D Insight Sue Shoolbread Editorial Leader 12 June 2006.
T H O M S O N S C I E N T I F I C Ann Wescott April 8, 2008 Prous Science Update SLA DPHT Spring Meeting 2008.
The conversion of Saul to St Paul (Michelangelo, 1542) Marcel Leist Doerenkamp-Zbinden Chair For Alternative in vitro Methods, University Konstanz, Konstanz.
Drug Research and Development (R&D) Karol Godwin DVM.
Dosimetry in Risk Assessment and a bit More Mel Andersen McKim Conference QSAR and Aquatic Toxicology & Risk Assessment June 27-29, 2006.
Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia Glenn A. Reinhart, Ph.D. Senior Group Leader Integrative.
Chemical Category Formation: Toxicology and REACH Dr Steven Enoch Liverpool John Moores University 14 th May 2009.
1 Enriching UK PubMed Central SPIDER launch meeting, Wolfson College, Oxford Paul Davey, UK PubMed Central Engagement Manager.
Jeffery Loo NLM Associate Fellow ’03 – ’05 chemicalinformaticsforlibraries.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
What Do Toxicologists Do?
Stefan Franzén Introduction to clinical trials.
Value of in vitro assays in your REACH dossier Frédérique van Acker 18 November 2014.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Stefan Franzén Introduction to clinical trials.
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
Marine Drug Development and Delivery Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University College of Pharmacy BELGAUM ,
Exploratory IND Studies
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
1 Innovative Science To Improve Public Health EDKB: Endocrine Disruptors Knowledge Base at the FDA Huixiao Hong, Ph.D. Center for Bioinformatics Division.
Mike Comber Consulting TIMES-SS Assessment of skin sensitisation hazard Presented on behalf of the TIMES-SS consortia.
May 2009 ChemAxon - What’s New?. What’s new and hot? All products have seen enhancements in the past 12 months BUT WHAT’S REALLY HOT?
Computational Toxicology and Virtual Development in Drug Design
Research & Science Advancing Risk Assessment Presentation March Association of Chemical Industry of the Czech Republic Monique Marrec Fairley.
Use of Machine Learning in Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
1 FDA Perspective on Nanomaterial- Containing Products Nakissa Sadrieh, Ph.D. Associate Director for Research Policy and Implementation Office of Pharmaceutical.
Lhasa ICH M7 Database – Use Cases Dr Angela White.
BioPaths-Catalyze Drug Discovery, Development and Clinical Research
Alessandro Pedretti MetaPies, an annotated database for metabolism analysis and prediction: results and future perspectives L’Aquila November 21, 2011.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Privacy Symposium / HIPAA Summit
The pharmaceutical R&D process years, costly ($30 Mn – $1300Mn)
The pharmaceutical R&D process
ECCR Overview/MLSCN. NIH Roadmap Series of initiatives designed to pursue major opportunities in biomedical research and gaps in current knowledge that.
1 OSHA’s Approach to Nanotechnology: Developing a Searchable "Health Effects Matrix" Database for Nanomaterials Utilizing Existing Published Data Janet.
Use of Machine Learning in Chemoinformatics
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
MDL Information Systems, Inc. Powering the Process of Invention Donna del Rey Director, Business Planning
Shows tendency for mergers. These big companies may be shrinking – much research is now outsourced to low cost countries like Latvia, India, China and.
Molecular Modeling in Drug Discovery: an Overview
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Decision Contexts in a Changing Toxicology Paradigm
ADME/Tox PredictionTox Prediction. The characterization of Absorption, Distribution, Metabolism, and Excretion (also known as ADME) and Toxicity are essential.
Lixia Yao, James A. Evans, Andrey Rzhetsky  Trends in Biotechnology 
PREDICT.
Drug Design and Drug Discovery
EFSA’s Chemical Hazards Database
Presentation transcript:

CONFIDENTIAL INFORMATION KnowTox, a Franco- Hungarian collaborative project relative to toxicity

CONFIDENTIAL INFORMATION Overview Aureus Pharma System ChemAxon and Aureus Relationships KnowTox project regarding drug- induced hepatotoxicity

CONFIDENTIAL INFORMATION Knowledge Base Integration Platform Query Interface Analysis/Display Applications The Aureus Pharma System

CONFIDENTIAL INFORMATION Aureus & ChemAxon Business partnership Business partnership Integration of ChemAxons tools into our system

CONFIDENTIAL INFORMATION Cheminformatic tools integrated in AurQUEST

CONFIDENTIAL INFORMATION Aureus & ChemAxon Business partnership Business partnership Integration of ChemAxons tools into our system Aureus Research and innovation Projects Aureus Research and innovation Projects Communication and Dissemination

CONFIDENTIAL INFORMATION Aureus Database Representation & Chemical Space Molecular descriptors & Fingerprints Virtual Screening Pharmacophoric Similarity 314 Hits AurQuest (Biological Activity) DiversityDB 45 Query structures Compounds Selection : 1. Molecular diversity and chemical originality 2. Compounds availability 38 compounds ordered for testing Virtual Screening Study to Identify New T-type Calcium Channel Blockers

CONFIDENTIAL INFORMATION Preliminary electrophysiology results

CONFIDENTIAL INFORMATION Internal projects Instant JChem Screen JKlustor LibMCS (being tested) Fragmenter (use in near future)

CONFIDENTIAL INFORMATION Aureus & ChemAxon Business partnership Business partnership Integration of ChemAxons tools into our system Aureus Research and innovation Projects Aureus Research and innovation Projects Communication and Dissemination Collaborative Eureka project : Collaborative Eureka project : Knowtox

CONFIDENTIAL INFORMATION Drug-induced toxicity Clinical safety Efficacy Formulation PK/Bioavailability Commercial Toxicology Cost of goods Unknown/other Attrition (%) Nature Reviews Drug Discovery 2004, 3: Chem. Res. Toxicol. 2007, 20: Drugs withdrawn recently for hepatotoxicity - Bromfenac reactive metabolite - Troglitazone reactive metabolite - Nefazodone reactive metabolite - Pemoline Predicting drug toxicity - Bioactivation alerts - Knowledge of toxicity pathways

CONFIDENTIAL INFORMATION Predictive Toxicology European REACH (Registration, Evaluation, and Authorization of Chemicals) system Alternative methods predictive tools in toxicology Collection of high-quality data European work programme FP7 Theme 1 - Health Theme 6 – Environment Joint Technology Initiative for Innovative Medicines InnoMed PredTox (FP6) PREDICTING SUITABILITY, SAFETY AND EFFICACY OF THERAPIES. HEALTH : Novel alternative testing strategies for use in pharmaceutical discovery and development. HEALTH : Bottlenecks in reduction, refinement and replacement of animal testing in pharmaceutical discovery and development. HEALTH : Promotion, development, validation, acceptance and implementation of QSARs (quantitative structure-activity relationship) for toxicology. HEALTH : Alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics. HEALTH : In silico modelling for ADMET outcomes. ENVIRONMENTAL TECHNOLOGIES: TECHNOLOGY ASSESSMENT, VERIFICATION AND TESTING ENV : In silico techniques for hazard-, safety-, and environmental risk-assessment. ENV : Defining of a long-term research strategy for the full replacement of animal tests for repeat dose systemic toxicity.

CONFIDENTIAL INFORMATION Global Project Knowledge base on drug-induced hepatotoxicity mined from literature Chemical and biological liver toxicity information for reference compounds associated with ADME properties Preclinical and clinical studies Query software tool for efficient data mining and exploitation Software tools for predicting metabolism and toxicity Metabolite prediction Metabolic stability prediction Hepatotoxicity prediction

CONFIDENTIAL INFORMATION Define and Design database structure Integrate literature Provide datasets for model building Define data needed for building the models Identify pertinent literature Build the model Help to define database structure and content Validate it Validate predictive software tools - sanofi-aventis - Aureus Pharma - ChemAxon/Univ. Budapest Partners and involvement

CONFIDENTIAL INFORMATION Deliverables New knowledgebase focused on hepatotoxicity Database structure suitable for internal data management purpose Metabolism prediction module Toxicity prediction software

CONFIDENTIAL INFORMATION KnowTox database 1 st version Molecules tested as or reported as hepatoxicants Biological quantitative / qualitative in vitro or in vivo activity Biological protocol description and details Bibliographical sources Links to external resources

CONFIDENTIAL INFORMATION Typical Queries 1. What are similar compounds to my potential hepatoxicant in term of given hepatotoxic biomarkers? 2. What are toxicological information regarding a particular chemical substructure or therapeutic class? 3. What are the histological endpoints of compounds of interest? 4. What type of cellular dysfunction injury has been described for compounds of interest? …

CONFIDENTIAL INFORMATION Ask a (chemical and / or biological) question Retrieve biological information AurQUEST Query software characteristics Retrieve a list of compounds Retrieve detailed protocols & links to bibliographical sources

CONFIDENTIAL INFORMATION Metabolizer characteristics Metabolizer ReactorBiotransformation library xenobiotics Metabolites

CONFIDENTIAL INFORMATION Toxicity prediction Toxicity Calculator FragmenterEvaluator Calculator plugin Calculator plugin Calculator plugin xenobiotics Metabolites + stability Toxicity data Predicted toxicity

CONFIDENTIAL INFORMATION KnowTox Added-Value Complete package for integration in drug discovery process Quick search and retrieval of information Improved efficiency to manage such undesirable events Better risk assessment (management and anticipation) Impact on probability of success to market new drugs

CONFIDENTIAL INFORMATION Acknowledgments Miklos Vargyas György Pirok Ferenc Csizmadia György Horvai Gilles Labbe Emmanuela Aly Frédéric Galli François Petitet Ismaïl Ijjaali KM & IT teams

CONFIDENTIAL INFORMATION « KnowTox »